+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tinnitus - Pipeline Review, H1 2020

  • ID: 5017474
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 45 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • MORE
Tinnitus - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2020, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • MORE
  • Introduction
  • Report Coverage
  • Tinnitus - Overview
  • Tinnitus - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tinnitus - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tinnitus - Companies Involved in Therapeutics Development
  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Sensorion SA
  • Tinnitus - Drug Profiles
  • AC-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AUT-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GW-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KB-3061 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OTO-313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Target Calcium Activated Potassium Channel for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RL-81 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target Calcium Activated Potassium Channel for Tinnitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tinnitus - Dormant Projects
  • Tinnitus - Discontinued Products
  • Tinnitus - Product Development Milestones
  • Featured News & Press Releases
  • Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Tinnitus, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2020
  • Tinnitus - Pipeline by Auris Medical Holding Ltd, H1 2020
  • Tinnitus - Pipeline by Autifony Therapeutics Ltd, H1 2020
  • Tinnitus - Pipeline by Cognosetta Inc, H1 2020
  • Tinnitus - Pipeline by Gateway Biotechnology Inc, H1 2020
  • Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2020
  • Tinnitus - Pipeline by Otonomy Inc, H1 2020
  • Tinnitus - Pipeline by Sensorion SA, H1 2020
  • Tinnitus - Dormant Projects, H1 2020
  • Tinnitus - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Tinnitus, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AudioCure Pharma GmbH
  • Auris Medical Holding Ltd
  • Autifony Therapeutics Ltd
  • Cognosetta Inc
  • Gateway Biotechnology Inc
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Sensorion SA
Note: Product cover images may vary from those shown
Adroll
adroll